title: A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
abstract: BACKGROUND
  9-Aminocamptothecin (9-AC) is a synthetic analogue of camptothecin. Phase I studies, identified the maximum tolerated dose as 1416 micrograms/m2/day x 3 as continuous intravenous infusion (CVI) with dose-limiting neutropenia.
  
  
  METHODS
  Eligible patients had stage IIIB or IV non-small-cell lung cancer (NSCLC) with measurable disease. Patients were initially treated at 1416 micrograms/m2/d x 3 by CVI followed by granulocyte-colony stimulating factor (G-CSF) support. This dose was decreased to 1100 micrograms/m2/d after the first 13 patients. Cycles were repeated every 14 days until tumor progression.
  
  
  RESULTS
  Fifty-eight patients were treated, thirteen at 1416 micrograms/m2/d and 45 at 1100 micrograms/m2/d. Fifty percent had adenocarcinoma and 17% squamous cell carcinoma. Seventy-one percent had stage IV disease. Five patients had a partial response (response duration 9-28 weeks) for an overall response rate of 8.6%, (95% confidence intervals (CI): 2.9%-19%). Median time to progression was 2.3 months and the median survival for the entire study population 5.4 months with a one-year survival rate of 30%. The one-year survival rate for 27 patients who received second line chemotherapy was 56.7%. Toxicities at 1416 micrograms/m2/d included grade 4 neutropenia and thrombocytopenia in six and five of 13 patients, respectively; at 1100 micrograms/m2/d these toxicities were observed in 12 and three of 45 patients, respectively.
  
  
  CONCLUSIONS
  9-AC has modest single-agent activity in previously untreated NSCLC. Its further evaluation at the dose and schedule employed in this study does not seem indicated. Exploration of more prolonged administration schedules may be warranted.
authors.affiliation: University of Chicago, Department of Medicine, USA.
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
authors.forename: R H
authors.initials: RH
authors.lastname: Ansari
authors.forename: G A
authors.initials: GA
authors.lastname: Masters
authors.forename: P C
authors.initials: PC
authors.lastname: Hoffman
authors.forename: A
authors.initials: A
authors.lastname: Klepsch
authors.forename: M J
authors.initials: MJ
authors.lastname: Ratain
authors.forename: D F
authors.initials: DF
authors.lastname: Sciortino
authors.forename: T E
authors.initials: TE
authors.lastname: Lad
authors.forename: S
authors.initials: S
authors.lastname: Krauss
authors.forename: P A
authors.initials: PA
authors.lastname: Fishkin
authors.forename: H M
authors.initials: HM
authors.lastname: Golomb
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor; C080125:9-aminocamptothecin; D002166:Camptothecin